These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30466755)

  • 21. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?
    Luskin MR; Stone RM
    J Oncol Pract; 2017 Aug; 13(8):471-480. PubMed ID: 28796964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.
    Buccisano F; Hourigan CS; Walter RB
    Curr Hematol Malig Rep; 2017 Dec; 12(6):547-556. PubMed ID: 29027628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
    Ehinger M; Pettersson L
    APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges of detecting measurable/minimal disease in acute leukemia.
    Zhang J; Oak J
    Semin Diagn Pathol; 2023 May; 40(3):216-220. PubMed ID: 37150656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
    Pettit K; Stock W; Walter RB
    Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal Residual Disease in Acute Myeloid Leukemia.
    Gomez-Arteaga A; Guzman ML
    Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of minimal residual disease in acute myeloid leukemia.
    Grimwade D; Vyas P; Freeman S
    Curr Opin Oncol; 2010 Nov; 22(6):656-63. PubMed ID: 20805746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.
    Schuurhuis GJ; Ossenkoppele GJ; Kelder A; Cloos J
    Expert Rev Hematol; 2018 Dec; 11(12):921-935. PubMed ID: 30466339
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
    Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
    Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MRD in AML: does it already guide therapy decision-making?
    Ossenkoppele G; Schuurhuis GJ
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):356-365. PubMed ID: 27913502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
    Chen X; Wood BL
    Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
    Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy.
    Schwind S; Jentzsch M; Bach E; Stasik S; Thiede C; Platzbecker U
    Curr Treat Options Oncol; 2020 Jan; 21(1):8. PubMed ID: 32002673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia.
    Chen X; Cherian S
    Clin Lab Med; 2021 Sep; 41(3):467-483. PubMed ID: 34304776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can we incorporate MRD assessment into clinical practice in AML?
    Ossenkoppele G; Schuurhuis GJ; van de Loosdrecht A; Cloos J
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):186-191. PubMed ID: 31204000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.